Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in... see more

Recent & Breaking News (NDAQ:VNDA)

Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

PR Newswire March 17, 2023

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

PR Newswire February 8, 2023

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023

PR Newswire February 1, 2023

Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference

PR Newswire January 6, 2023

Fanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study

PR Newswire December 19, 2022

Vanda Pharmaceuticals Provides an Update to HETLIOZ® ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch

PR Newswire December 16, 2022

Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Litigation

PR Newswire December 13, 2022

Vanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety

PR Newswire December 2, 2022

Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences

PR Newswire November 8, 2022

Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results

PR Newswire November 2, 2022

Vanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022

PR Newswire October 26, 2022

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera

PR Newswire October 21, 2022

Vanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics

PR Newswire September 29, 2022

Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

PR Newswire September 8, 2022

VANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER

PR Newswire September 7, 2022

Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results

PR Newswire August 3, 2022

Vanda Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 3, 2022

PR Newswire July 27, 2022

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Vanda Pharmaceuticals Inc.

Newsfile June 30, 2022

Vanda Pharmaceuticals Announces Participation in the Jefferies 2022 Global Healthcare Conference

PR Newswire June 2, 2022

Vanda Pharmaceuticals Announces Presentations at SLEEP 2022

PR Newswire May 31, 2022